TRANSTHYRETIN AMYLOID CARDIOMYOPATHY (ATTR-CM)
Clinical trials for TRANSTHYRETIN AMYLOID CARDIOMYOPATHY (ATTR-CM) explained in plain language.
Never miss a new study
Get alerted when new TRANSTHYRETIN AMYLOID CARDIOMYOPATHY (ATTR-CM) trials appear
Sign up with your email to follow new studies for TRANSTHYRETIN AMYLOID CARDIOMYOPATHY (ATTR-CM), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug aims to cut heart deaths in rare heart condition
Disease control Recruiting nowThis study tests an experimental drug called NNC6019-0001 in people with transthyretin amyloid cardiomyopathy (ATTR-CM), a condition where abnormal proteins build up in the heart. About 1,280 adults will receive either the drug or a placebo by IV, alongside their usual heart trea…
Matched conditions: TRANSTHYRETIN AMYLOID CARDIOMYOPATHY (ATTR-CM)
Phase: PHASE3 • Sponsor: Novo Nordisk A/S • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New drug duo aims to stop rare heart disease in its tracks
Disease control Recruiting nowThis phase 2b trial tests whether adding ALXN2220 to eplontersen works better than eplontersen alone for adults with transthyretin amyloid cardiomyopathy (ATTR-CM), a condition where abnormal proteins build up in the heart. About 326 participants will receive either the combinati…
Matched conditions: TRANSTHYRETIN AMYLOID CARDIOMYOPATHY (ATTR-CM)
Phase: PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New heart drug acoramidis tested in Real-World setting
Disease control Recruiting nowThis observational study follows up to 2,000 adults with ATTR-CM, a serious heart condition, who are starting treatment with acoramidis as part of their normal care. Researchers will track patient characteristics, how the drug is used, and its effects on heart function and qualit…
Matched conditions: TRANSTHYRETIN AMYLOID CARDIOMYOPATHY (ATTR-CM)
Sponsor: Bayer • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC